Drugs / Cofetuzumab Pelidotin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04189614 | Feb 2020 → May 2026 | non-small cell lung carcinoma | AbbVie | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02222922 | Oct 2014 → Nov 2019 | neoplasm | Pfizer | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cofetuzumab Pelidotin | “First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.” PMID 34083232 ↗ Jun 2021 |
| Known as | Cofetuzumab pelidotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989983 ↗ |
| Known as | Cofetuzumab pelidotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989983 ↗ |
| Known as | PF-06647020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02222922 ↗ |
| Modality | Other / unclassified | “a PTK7-Targeting Antibody Drug Conjugate” NCT04189614 ↗ |
| Route | Intravenous | “Patients received PF-06647020 intravenously every 3 weeks at 0.2-3.7 mg/kg or every 2 weeks at 2.1-3.2 mg/kg” PMID 34083232 ↗ Jun 2021 |
| Target | PTK7 | “First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.” PMID 34083232 ↗ Jun 2021 |